TY  - JOUR
T1  - A fatal side effect of piperacillin/tazobactam use: a case report.
AU  - Duyan, Murat
AU  - Günlü, Serhat
AU  - Sarıdaş, Ali
AU  - Cander, Basar
AU  - Solaç, Yıldızhan
PY  - 2021
DA  - December
Y2  - 2021
JF  - Eurasian Journal of Critical Care
JO  - Eurasian j Crit Care
PB  - Acil Tıp Uzmanları Derneği
WT  - DergiPark
SN  - 2667-8721
SP  - 119
EP  - 121
VL  - 3
IS  - 3
LA  - en
AB  - Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident. A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection. She has had normal ECG findings before the antibacterial therapy. After the treatment, the patient worsens due to long QT which is predisposed to torsades de pointes. As a result of the researches, it was understood that the cause of long QT was piperacillin/tazobactam. We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.
KW  - torsades de pointes
KW  - drug-induced long QT syndrome
KW  - piperacillin/tazobactam
KW  - t-wave inversion
KW  - urinary tract infection
KW  - arrest
CR  - :1.         Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006;17(3):333-336. doi:10.1111/j.1540-8167.2006.00408.x
CR  - 2.         Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17(1):43-51. doi:10.1097/00001573-200201000-00007
CR  - 3.         Woosley RL. QT Drug Lists by Risk Groups. AZ: Arizona Center for Research and Education on Therapeutics. Published 2009. Accessed September 1, 2021. http:// www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
CR  - 4.         Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316(3):1098-1106. doi:10.1124/jpet.105.093393
CR  - 5.         Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. doi:10.2165/11531850-000000000-00000
CR  - 6.         Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J. 2013;13(1):152-155. doi:10.12816/0003211
CR  - 7.         Piperacillin and tazobactam: Drug information. Published December 6, 2020. Accessed semtember 1, 2021. . https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information search=piperacillin%20tazobactam&source=panel_search_result&selectedTitle=1~104&usage_type=panel&kp_tab=drug_general&display_rank=1#F210382
UR  - https://dergipark.org.tr/tr/pub/ejcc/issue//992697
L1  - https://dergipark.org.tr/tr/download/article-file/1963337
ER  -